Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Taxes (2017 - 2019)

Avalo Therapeutics filings provide 3 years of Current Taxes readings, the most recent being $551671.0 for Q4 2019.

  • On a quarterly basis, Current Taxes fell 72.85% to $551671.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $551671.0, a 72.85% decrease, with the full-year FY2019 number at $551671.0, down 72.85% from a year prior.
  • Current Taxes hit $551671.0 in Q4 2019 for Avalo Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $3.2 million in Q3 2017 to a low of $551671.0 in Q4 2019.
  • Median Current Taxes over the past 3 years was $2.1 million (2018), compared with a mean of $1.9 million.
  • Biggest five-year swings in Current Taxes: fell 10.04% in 2018 and later crashed 72.85% in 2019.
  • Avalo Therapeutics' Current Taxes stood at $2.3 million in 2017, then fell by 10.04% to $2.0 million in 2018, then crashed by 72.85% to $551671.0 in 2019.
  • The last three reported values for Current Taxes were $551671.0 (Q4 2019), $1.0 million (Q3 2019), and $1.4 million (Q2 2019) per Business Quant data.